

December 17, 2015
Taiho Pharmaceutical Co., Ltd.
Meiji Seika Pharma Co., Ltd.

Taiho and Meiji Enter Into a Co-marketing Agreement in Japan for TAC-202 (bilastine), a Treatment for Allergic Disorders

Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director: Masayuki Kobayashi) and Meiji Seika Pharma Co., Ltd. (HQ: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that the two companies have signed a co-marketing agreement in Japan for an oral anti-allergy drug TAC-202 (generic name: bilastine) for which Taiho submitted a new drug application to the Ministry of Health, Labour and Welfare (MHLW) in this November.

Under this agreement, Meiji will acquire the co-marketing right of TAC-202 in Japan, and the both companies will start to provide drug information to medical care providers after Taiho receives approval to manufacture and market the drug in Japan from MHLW. Meiji will make an upfront payment and sales milestone payments contingent upon the achievement of sales goals.

Bilastine is an innovative anti-histamine product discovered by Faes Farma S.A. in Spain (HQ: Leioa, President: Mariano Ucar Angulo) and was first approved in European Union in 2010. Taiho has developed the drug after signing a license agreement with Faes Farma in July 2012 for the development and marketing rights in Japan. The product has been successfully approved in over 90 countries and regions* and marketed by several partners under the license from Faes Farma for the treatment of allergic rhinitis and urticaria.

* As of May 2015

Taiho and Meiji will dedicate efforts to further contribute to patients and medical care providers in the area of allergy/immunology .

About Faes Farma S.A.

Faes Farma S.A. is one of the leading Spanish pharmaceutical companies, focused on research, manufacture and commercialization of innovative medicines.

With strong presence also in Portugal, Latin America and Africa, Faes Farma is now developing an intense process of internationalization. Bilastine shall be a key element in this process. For more information about Faes Farma, please visit the company's website at <http://www.faes.es/>.